The expression of P16, P53, and PTEN in polyps (including those undergoing endocrine therapy in premenopausal and postmenopausal women), sporadic polyps, and endometrial carcinoma.

This dataset was collected by the researchers in clinical practice, mainly using SPSS 21 for analysis, overall analysis, and processing. The table involves many row label sets and column labels, mainly focusing on column labels, including patient groups (1, 2, 3, 4, 5, 6, 7, 8), which mainly correspond to (1) premenopausal TAM; 2. Premenopausal TOR; 3. Postmenopausal TAM; 4. Post menopausal TOR; 5. Premenopausal polyps; 6. Postmenopausal polyps; 7. Premenopausal endometrial cancer; 8. Postmenopausal endometrial cancer), age (unit: years), whether menopause (1: yes, 2: no), BMI: keep 2 decimal places (unit: Kg/m2), number of deliveries, hypertension (1: yes, 2: no), diabetes (1: yes, 2: no), abnormal uterine bleeding (1: yes, 2: no), type of medication (1, TAM; 2, TOR), time of medication (unit: month), endometrial thickness (unit: mm), maximum diameter of uterine space occupation (unit: mm), pathological results, The percentage of positive cells for P16, P53, PTEN glands (≤ 10% is 1 point, 10%~50% is 2 points, 50%~75% is 3 points,>75% is 4 points), staining intensity ("-" is 0 points, "+" is 1 point, "++" is 2 points, "+++" is 3 points), staining score (percentage of positive cells * staining intensity), staining grade (0-3 points are negative, 3-6 points are+, 6-8 points are++, 8-12 points are++++, negative is 0 points, "+" is 1 point, "++" is 2 points, "+++" is 3 points), partial endometrial cancer, sporadic The lack of medication types and duration for endometrial polyps is in accordance with the experimental design and should not be treated.